Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

被引：0
作者：
M. T. Driessen
J. Whalen
B. Seewoodharry Buguth
L. A. Vallejo-Aparicio
I. P. Naya
Y. Asukai
B. Alcázar-Navarrete
M. Miravitlles
F. García-Río
N. A. Risebrough
机构：
[1] Value Evidence and Outcomes,Departamento de Evaluación de Medicamentos
[2] GSK,Pneumology Department
[3] ICON Health Economics,undefined
[4] ICON plc,undefined
[5] GSK,undefined
[6] Global Respiratory Franchise,undefined
[7] GSK,undefined
[8] Hospital de Alta Resolución de Loja,undefined
[9] Hospital Universitari Vall d’Hebron,undefined
[10] Hospital Universitario La Paz-IdiPAZ,undefined
[11] ICON Health Economics,undefined
[12] ICON,undefined
来源：
Respiratory Research | / 19卷
关键词：
Bronchodilators; Chronic obstructive pulmonary disease; Cost effectiveness; Economic evaluation; Health resources; LAMA/LABA; National Healthcare System perspective; QALY; Spain; Utility;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 242 条
[51]  
O’Dell D(undefined)undefined undefined undefined undefined-undefined
[52]  
Church A(undefined)undefined undefined undefined undefined-undefined
[53]  
Fahy WA(undefined)undefined undefined undefined undefined-undefined
[54]  
Decramer M(undefined)undefined undefined undefined undefined-undefined
[55]  
Anzueto A(undefined)undefined undefined undefined undefined-undefined
[56]  
Kerwin E(undefined)undefined undefined undefined undefined-undefined
[57]  
Kaelin T(undefined)undefined undefined undefined undefined-undefined
[58]  
Richard N(undefined)undefined undefined undefined undefined-undefined
[59]  
Crater G(undefined)undefined undefined undefined undefined-undefined
[60]  
Donohue JF(undefined)undefined undefined undefined undefined-undefined
12345678910